NCT02227199 2025-11-18
BV-ICE
University of Washington
Phase 1/2 Completed
Clinical Trials
11 trialsNCT03187210 2025-03-30
BAL
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Suspended
NCT02096042 2023-10-10
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02098512 2022-10-27
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
New York Medical College
Phase 1/2 Unknown
NCT02429375 2022-05-12
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02686346 2021-12-07
BV-ICE
The Lymphoma Academic Research Organisation
Phase 1/2 Completed
NCT01657331 2020-07-17
SGN+Benda
Columbia University
Phase 1/2 Completed
NCT02729961 2019-10-10
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
Phase 1/2 Withdrawn
NCT02243436 2019-04-24
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Completed
NCT02408042 2017-06-27
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
Phase 1/2 Withdrawn
NCT01620229 2014-04-21
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn